AG真人官方

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

BOSTON--(BUSINESS WIRE)-- (Nasdaq: IRWD) today announced that management will participate in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7^th at 12:00 p.m. ET at the New York Hilton Midtown.

A live webcast of Ironwood鈥檚 fireside chat will be accessible through the Investors section of the company鈥檚 website at . A replay of the webcast will be available on Ironwood鈥檚 website following the conference.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (Nasdaq: IRWD) is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases. Ironwood is advancing apraglutide, a next-generation, long-acting synthetic GLP-2 analog being developed for short bowel syndrome patients who are dependent on parenteral support. In addition, Ironwood has been a pioneer in the development of LINZESS^庐 (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). LINZESS is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. Building upon our history of innovation, we keep patients at the heart of our R&D and commercialization efforts to reduce the burden of diseases and address significant unmet needs.

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, with a site in Basel, Switzerland.

We routinely post information that may be important to investors on our website at . In addition, follow us on and on .

View source version on businesswire.com:

Company contact:

Greg Martini

[email protected]

Investors:

Precision AQ (formerly Stern Investor Relations)

Stephanie Ascher

[email protected]

Source: Ironwood Pharmaceuticals, Inc.